AIM
BEAM icon

ARK Investment Management’s Beam Therapeutics BEAM Stock Holding History

ARK Investment Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$351M Sell
10,234,862
-1,898,571
-16% -$57.3M 2.28% 15
2026
Q1 		$289M Sell
12,133,433
-333,756
-3% -$9.26M 2.25% 14
2025
Q4 		$346M Buy
12,467,189
+1,428,355
+13% +$36.4M 2.29% 12
2025
Q3 		$268M Buy
11,038,834
+2,190,993
+25% +$43.6M 1.59% 16
2025
Q2 		$151M Buy
8,847,841
+367,752
+4% +$6.4M 1.1% 27
2025
Q1 		$166M Buy
8,480,089
+1,412,060
+20% +$37M 1.66% 19
2024
Q4 		$175M Buy
7,068,029
+536,930
+8% +$13.7M 1.46% 20
2024
Q3 		$160M Sell
6,531,099
-1,095,040
-14% -$28.3M 1.46% 21
2024
Q2 		$179M Sell
7,626,139
-556,035
-7% -$13.7M 1.59% 22
2024
Q1 		$270M Sell
8,182,174
-1,211,715
-13% -$37.8M 1.87% 15
2023
Q4 		$256M Buy
9,393,889
+609,998
+7% +$15.2M 1.51% 21
2023
Q3 		$211M Buy
8,783,891
+401,296
+5% +$10.8M 1.62% 20
2023
Q2 		$268M Sell
8,382,595
-190,834
-2% -$6.19M 1.77% 19
2023
Q1 		$263M Buy
8,573,429
+360,298
+4% +$14.2M 1.8% 19
2022
Q4 		$321M Sell
8,213,131
-277,805
-3% -$12.4M 2.78% 12
2022
Q3 		$405M Sell
8,490,936
-301,128
-3% -$17.2M 2.82% 12
2022
Q2 		$309M Buy
8,792,064
+591,315
+7% +$23.5M 1.83% 16
2022
Q1 		$470M Buy
8,200,749
+217,348
+3% +$14.3M 1.96% 15
2021
Q4 		$636M Buy
7,983,401
+1,141,679
+17% +$97.8M 1.92% 17
2021
Q3 		$595M Buy
6,841,722
+380,355
+6% +$38.2M 1.43% 21
2021
Q2 		$832M Buy
6,461,367
+1,682,263
+35% +$134M 1.55% 17
2021
Q1 		$383M Buy
4,779,104
+3,647,481
+322% +$347M 0.76% 40
2020
Q4 		$92.4M Buy
+1,131,623
New +$55.6M 0.25% 74

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ARK Investment Management's BEAM Position: Q2 2026 in Review

ARK Investment Management reduced its Beam Therapeutics (BEAM) stake by 16% in Q2 2026, selling an estimated $57.3M and leaving 10,234,862 shares worth $351M. The position accounts for 2.28% of the portfolio, ranked #15.

ARK Investment Management first reported a position in BEAM in Q4 2020 and has held it in 23 quarters since. The position peaked at $832M in Q2 2021. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • ARK Investment Management held 10,234,862 shares of Beam Therapeutics worth $351M as of Q2 2026.
  • ARK Investment Management sold 1,898,571 Beam Therapeutics shares in Q2 2026, an estimated $57.3M.
  • Beam Therapeutics made up 2.28% of ARK Investment Management's portfolio in Q2 2026, its #15 holding.
  • ARK Investment Management first reported a position in Beam Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • ARK Investment Management's Beam Therapeutics position peaked at $832M in Q2 2021.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on ARK Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.